Search
forLearn
5 / 801 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn ACETYL TETRAPEPTIDE-2
learn ppg-26-buteth-26
learn sh-Polypeptide-7
Research
5 / 1000+ results
research Physiologic functions of PP2A: Lessons from genetically modified mice
Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.
research Ppp2r2a Knockout Mice Reveal That Protein Phosphatase 2A Regulatory Subunit, PP2A-B55α, Is an Essential Regulator of Neuronal and Epidermal Embryonic Development
The PP2A-B55α protein is essential for brain and skin development in embryos.
research Conditional Knockout in Mice Reveals the Critical Roles of Ppp2ca in Epidermis Development
PP2Acα is essential for proper hair and skin development.
research Wnt signaling in skin organogenesis
Wnt signaling is crucial for skin and hair development and its disruption can cause skin tumors.
research Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study
Sodium selenate was found to be safe and possibly slows Alzheimer's progression, but more research is needed.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community Update for PP405 - phase 2b underway
PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.